A recent ruling by a Delaware federal judge has nullified Natera’s substantial $96 million patent infringement verdict against CareDx. The decision came after the court determined that the claims asserted in Natera’s patents, which pertain to DNA tests administered to organ transplant recipients, were deemed invalid. This significant legal development marks a pivotal moment in the ongoing litigation between the two companies over the use of innovative technologies in genetic testing.
The implications of invalidating these patents underscore the complexities of intellectual property law, especially within the rapidly advancing field of medical diagnostics. For more detailed insights into the ruling and its potential impact on both companies, as well as the broader industry, the case details are available on Law360.